Lobeglitazone as an Effective and Safe Addition to Metformin and Sitagliptin Therapy in Type 2 Diabetes: Results from a 52-Week Multicentre Phase III Trial
Posted inClinical Updates Wellness & Lifestyle

Lobeglitazone as an Effective and Safe Addition to Metformin and Sitagliptin Therapy in Type 2 Diabetes: Results from a 52-Week Multicentre Phase III Trial

This phase III trial showed that adding lobeglitazone to metformin and sitagliptin significantly improves glycaemic control and insulin sensitivity with favorable safety over 52 weeks in Korean patients with type 2 diabetes inadequately controlled by dual therapy.
Metformin as an Adjunct to Chemoradiotherapy in Locally Advanced Cervical Cancer: Insights on Safety, Tolerability, and Feasibility from a Phase II Randomized Trial
Posted inClinical Updates Wellness & Lifestyle

Metformin as an Adjunct to Chemoradiotherapy in Locally Advanced Cervical Cancer: Insights on Safety, Tolerability, and Feasibility from a Phase II Randomized Trial

This phase II study shows that adding metformin to standard chemoradiotherapy in locally advanced cervical cancer is safe, well tolerated, and feasible, with no significant increase in severe adverse events and successful biomarker-based tumor hypoxia assessments.
Evaluating Metformin Addition to Paclitaxel/Carboplatin in Advanced and Recurrent Endometrial Cancer: Insights from an NRG Oncology/GOG Phase II/III Trial
Posted inClinical Updates Wellness & Lifestyle

Evaluating Metformin Addition to Paclitaxel/Carboplatin in Advanced and Recurrent Endometrial Cancer: Insights from an NRG Oncology/GOG Phase II/III Trial

This phase II/III study assessed whether adding metformin to standard paclitaxel and carboplatin improved outcomes in advanced and recurrent endometrial cancer. The trial was stopped early due to lack of survival benefit and potential harm, highlighting the need for alternative therapeutic strategies.